Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome

Journal of Association of Physicians of India

Volumn 44, Issue 3, 1996, Pages 181-183

  Nair, Reena ^a   Saikia, T K ^a   Gopal, R ^a   Nair, Chandrica N ^a   Soman, Chitralekha S ^a   Advani, S H ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030089636     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Koeffler HP. Myelodysplastic syndrome (preleukemia). Sem Hematol 1986; 23 : 284-299.
2. Griffin J, Munroe D, Mayor P et al. Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol 1982; 10 : 774-781.
3. Bennett JM, Catovsky D,Daniel MT et al. Proposals for classification of myelodysplastic syndromes. Br J Hematol 1982; 51 : 189-199.
4. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53 : 457-481.
5. Cheson BD, Jasperse DM, Simon R et al. A critical appraisal of low dose cytosine arabinoside in patients with acute non lymphoblastic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4 : 1857-1864.
6. Cheson BD, Simon R. Low dose Ara-C in acute non lymphocytic leukemia and myelodysplastic syndromes. A review of 20 years experience. Semin Oncol 1987; 14 : 126-133 (Suppl 1).
7. Miller KM, Kim K, Morrison FS et al. Evaluation of low dose Ara-C versus supportive care in the treatment of myelodysplastic syndromes. An intergroup study by the Eastern Co-operative Oncology Group and the Southwest Oncology Group. Blood 1988; 72 : 215a (abstr 771).
8. Thompson JA, Lee DJ, Kidd P et al. Subcutaneous granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndrome. Toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7 : 629-637.
9. Herrmann F, Lindemann A, Klein H et al. Effects of recombinant human granulocyte - macrophage colony stimulating factor in patients with myelodysplastic syndromes with excess blasts. Leuk 1989; 3 : 335-338.
10. Picozzi VT, Swanson GF, Morgan R et al. 13 cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 1986; 4 : 589.
11. 3 : In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69 : 1399.
12. Gisslinger II, Chott A, Linkesch W et al. Long term alpha-interferon therapy in myelodysplastic syndromes. Leuk 1990; 4 : 91-94.
13. Koeffler HP, Heitjan D, Merelsmann R et al. Randomised study of 13-cis retinoic acid versus placebo in myelodysplastic disorders. Blood 1988; 71 : 703.
14. Venditti A, Stasi R, Masi M, et al. All-trans retinoic acid plus low dose of cytarabine for the treatment of "poor risk" acute myeloid leukemias. Ann Hematol 1993; 6 : 59-60.
15. Hoelzer D, Ganser A, Seilpet G, et al. Simultaneous treatment with recombinant human granulocyte-macrophage colony-stimulating factor and low dose cytosine arabinoside in patients with myelodysplastic syndromes. Blood 1989; 74 : 118 (abstr).